{"brief_title": "Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes", "brief_summary": "The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.", "condition": "Diabetes Mellitus, Type 2", "intervention_type": "Drug", "intervention_name": "Muraglitazar", "criteria": "Inclusion Criteria: - Type 2 diabetes; - Serum triglyceride concentration < or = 600 mg/dL; - Body mass index < or = 37 kg/m2 Exclusion Criteria: - Type 1 diabetes; - History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months; - Congestive heart failure (NYHA Class III and IV); - Uncontrolled hypertension; - Women of Child Bearing Potential - History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "id": "NCT00094991.xml"}